← Research library

Cerebrolysin in 67 first-degree relatives of people with Alzheimer’s disease

Observational study · 2018

What was studied
67 first-degree relatives, 27 with objectively confirmed cognitive difficulty and 40 without.
Main finding
Clinicians rated 77.6% improved after the course. Both baseline subgroups received Cerebrolysin.

Clinician-rated improvement · 77.6% of 67 · After the one-month course

Reported findings and study design

Before-and-after study, stratified by baseline cognitive difficulty.

Population or model 67 first-degree relatives, 27 with objectively confirmed cognitive difficulty and 40 without.

Dose, route and schedule

Cerebrolysin 20 mL intravenously in 100 mL saline per treatment day for a one-month course.

Protocol source ↗ · Original indexed abstract, treatment cohort and outcome summary.

Results · Original indexed abstract, treatment cohort and outcome summary.
MeasureResultComparison, timing and statistics
Clinician-rated improvement77.6% of 67After the one-month course
MMSE and MoCABoth subgroups improved significantly versus baselineThe abstract gives no arm-level score changes.

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • The abstract describes no untreated group. The measurements were short term. Overlap with other reports from the same center is unresolved.

Related publications may describe some of the same participants or experiments.

Source details

Original indexed abstract, treatment cohort and outcome summary.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

N. D. Selezneva, I. F. Roshchina, G. I. Korovaitseva, S. I. Gavrilova. Cerebrolysin in 67 first-degree relatives of people with Alzheimer’s disease Korsakov Journal of Neurology and Psychiatry. 2018;118(10):30–36.

Study source ↗ · DOI 10.17116/jnevro201811810130 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards